Evidence map›Paper›PMID 33208190›Full record

SynthesisAlzheimer's research & therapy2020

Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.

Filipa Landeiro, Seher Mughal, Katie Walsh, Elsbeth Nye, Jasmine Morton, Harriet Williams, Isaac Ghinai, Yovanna Castro, José Leal, Nia Roberts and 12 more

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07420426 (Instant Message-delivered Personalised Acceptance and Commitment Therapy), which is not on this map. Cited by 57 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 6 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07420426 narecruitingnot on this mapstarted 2025, after this paper: background citation

Instant Message-delivered Personalised Acceptance and Commitment Therapy (IMPACT) for Neuropsychiatric Symptoms in Persons With Mild Cognitive Impairment: a Mixed Methods Study

TypeinterventionalSponsorThe University of Hong KongRan2025 to 2026Enrolled160ConditionsMild Cognitive Impairment (MCI)Armsautomated instant message-guided neuropsychiatric symptoms management, general mental health management
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 6 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The impact of hearing loss on annual incident age-associated dementia cases and quality of life in the United States.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 5 countries.

Filipa LandeiroHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK. filipa.landeiro@ndph.ox.ac.uk.ORCID 0000-0003-2842-2195
Seher MughalHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Katie WalshHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Elsbeth NyeHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Jasmine MortonHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Harriet WilliamsHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Isaac GhinaiHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Yovanna CastroGlobal Access, Centre of Excellence, F. Hoffmann-La Roche Ltd, Bldg 1, CH-4070, Basel, Switzerland.
José LealHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Nia RobertsBodleian Health Care Libraries, Old Road Campus, University of Oxford, Oxford, OX3 7LF, UK.
Helena WaceHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Ron HandelsAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands.
Pascal LecomteGlobal Head Health Economic Modelling and Methodology, Novartis Pharma AG, 4002, Basel, Switzerland.
Anders GustavssonDepartment of Neurobiology, Care Science and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden.
Emilse Roncancio-DiazLife Sciences, GE Healthcare Life Sciences, Amersham, UK.
Mark BelgerGlobal Statistical Sciences, Eli Lilly and Company, Indianapolis, IN 46225, USA.
Gurleen S JhutiGlobal Access, Centre of Excellence, F. Hoffmann-La Roche Ltd, Bldg 1, CH-4070, Basel, Switzerland.
Jacoline C BouvyScience Policy and Research Programme, National Institute for Health and Care Excellence, 10 Spring Gardens, London, SW1A 2BU, UK.
Michele H PotashmanValue and Access, Biogen, 225 Binney St, Cambridge, MA, 02139, USA.
Antje Tockhorn-HeidenreichGPORWE International, Eli Lilly and Company, Indianapolis, IN 46225, USA.
Alastair M GrayHealth Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
ROADMAP consortium
University of Oxford · GBEli Lilly (United States) · USKarolinska Institutet · SERoche (Switzerland) · CHBiogen (United States) · USNational Institute for Health and Care Excellence · GBNovartis (Switzerland) · CH

Funding

Medical Research Council MR/L023784/1
6 · The paper itself

Abstract

backgroundObtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions.

aimsTo provide an overview of which quality of life instruments are being used to assess HR-QoL in people with predementia AD, MCI or dementia; and, to summarise their reported HR-QoL levels at each stage of the disease and by type of respondent.

methodsWe systematically searched for and reviewed eligible studies published between January 1990 and the end of April 2017 which reported HR-QoL for people with predementia AD, MCI or dementia. We only included instruments which are preference-based, allowing index scores/utility values to be attached to each health state they describe based on preferences obtained from population surveys. Summary results were presented by respondent type (self or proxy), type of instrument, geographical location and, where possible, stage of disease. Health state utility values derived using the EuroQoL 5-Dimensions (EQ-5D) were meta-analysed by pooling reported results across all studies by disease severity (MCI, mild, mild to moderate, moderate, severe dementia, not specified) and by respondent (person with dementia, carer, general public, not specified), using a fixed-effects approach.

resultsWe identified 61 studies which reported HR-QoL for people with MCI or dementia using preference-based instruments, of which 48 used the EQ-5D. Thirty-six studies reported HR-QoL for mild and/or moderate disease severities, and 12 studies reported utility values for MCI. We found systematic differences between self-rated and proxy-rated HR-QoL, with proxy-rated utility valued being significantly lower in more severe disease states.

conclusionsA substantial literature now exists quantifying the impact of dementia on HR-QoL using preference-based measures, giving researchers and modellers a firmer basis on which to select appropriate utility values when estimating the effectiveness and cost-effectiveness of interventions in this area. Further research is required on HR-QoL of people with preclinical and prodromal AD and MCI, possible differences by type of dementia, the effects of comorbidities, study setting and the informal caregiver's own HR-QoL, including any effect of that on their proxy-ratings.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDementiaCaregiversHumansQuality of LifeAlzheimer’s diseaseDementiaQuality of lifeSystematic literature review

Identifiers

PMID33208190
PMCPMC7677851
OpenAlexW3106078803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.